ArticleJournal of investigative medicine : the official publication of the American Federation for Clinical Research2015
Red Blood Cells Store and Release Interleukin-33.
Article in Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 39 citations in OpenAlex.
- Heme and iron toxicity in the aged spleen impairs T cell immunity through iron deprivation.Nature aging · 2025Article
- Erythronecroptosis: an overview of necroptosis or programmed necrosis in red blood cells.Molecular and cellular biochemistry · 2024Review
- Role of Macrophages in Sickle Cell Disease Erythrophagocytosis and Erythropoiesis.International journal of molecular sciences · 2023Review
- Are IL-1 family cytokines important in management of sickle cell disease in Sub-Saharan Africa patients?Frontiers in immunology · 2023Article
- The IL-33/ST2 Pathway in Cerebral Malaria.International journal of molecular sciences · 2022Review
- Red Blood Cell-Conditioned Media from Non-Alcoholic Fatty Liver Disease Patients Contain Increased MCP1 and Induce TNF-α Release.Reports of biochemistry & molecular biology · 2022Article
- The Paradigm Change of IL-33 in Vascular Biology.International journal of molecular sciences · 2021Review
- A Review of Current Management of Knee Hemarthrosis in the Non-Hemophilic Population.Cartilage · 2021Review
- IL-33 promotes anemia during chronic inflammation by inhibiting differentiation of erythroid progenitors.The Journal of experimental medicine · 2020Article
- Article
- IL33 and Mast Cells-The Key Regulators of Immune Responses in Gastrointestinal Cancers?Frontiers in immunology · 2020Review
- Pleural Effusion IL-33/sST2 Levels and Effects of Low and High IL-33/sST2 Levels on Human Mesothelial Cell Adhesion and Migration.Inflammation · 2019Article
- Genetic programming of macrophages generates an in vitro model for the human erythroid island niche.Nature communications · 2019Article
- Red blood cell storage lesion: causes and potential clinical consequences.Blood transfusion = Trasfusione del sangue · 2019Review
- Red blood cells are dynamic reservoirs of cytokines.Scientific reports · 2018Article
- Interleukin-33 in Systemic Sclerosis: Expression and Pathogenesis.Frontiers in immunology · 2018Review
- Interleukin-33 regulates tissue remodelling and inhibits angiogenesis in the eye.The Journal of pathology · 2017Article
- Red cell DAMPs and inflammation.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2016Review
- Controlling the burn and fueling the fire: defining the role for the alarmin interleukin-33 in alloimmunity.Current opinion in organ transplantation · 2016Review
- IL-33 reflects dynamics of disease activity in patients with autoimmune hemolytic anemia by regulating autoantibody production.Journal of translational medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Interleukin-33 (IL-33) is a member of the IL-1 cytokine superfamily that potently drives production of a variety of cytokines and contributes to the pathogenesis of inflammatory diseases. The IL-33 is a nuclear protein and is released from apoptotic or necrotic cells. Serum IL-33 levels are increased in various diseases, such as atopic dermatitis, chronic hepatitis C infection, and asthma. Here, we show that red blood cells (RBCs) are one of the major sources of plasma IL-33. The IL-33 levels are significantly increased in supernatants from lysed RBCs. Plasma IL-33 levels are increased in patients during hemolysis, and plasma IL-33 levels show a positive correlation with degree of hemolysis. The IL-33 protein and messenger RNA levels were detected in the late stages of differentiation in ex vivo primary human erythroid progenitor cell cultures, suggesting that IL-33 is expressed during maturation of RBCs. Furthermore, hemoglobin depleted red cell lysates induced IL-8 expression in human epithelial cells. This effect was attenuated in IL-33 decoy receptor expressing cells and was enhanced in IL-33 receptor expressing cells. These results suggest that erythroid progenitor cells produce IL-33 and circulating RBCs represent a major source of IL-33 that is released upon hemolysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.